Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BYSI with free AI briefings, catalyst countdowns, and dilution alerts.

BYSI · BeyondSpring Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6.5M Cash on Hand
5.6mo Cash Runway
Follow BYSI by email Get an email when BYSI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BYSI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Plinabulin Non-Small Cell Lung Cancer Phase 3 · NCT02504489 Completed
Doxorubicin Chemotherapy-induced Neutropenia Phase 3 · NCT03294577 Unknown

Also used in these trials (approved or third-party drugs, not BYSI's own candidates): Docetaxel Anhydrous, Pegfilgrastim, Ipilimumab, Nivolumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BYSI holds $6.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 5.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BYSI files for a raise →

👥 Who Owns BYSI

Insiders 22.6% Other 5%+ holders 7.4% Institutions (26 holders) 13.2% Public and other holders 56.8%
HolderTypeShares% of sharesAs of
Lan Huang
Chief Executive Officer, Director, 10% o · +55,144 options
Insider 5,293,444 12.78% 2026-06-30
Decheng Capital China Life Sciences USD
10% owner
Insider 4,028,036 9.73% 2025-10-16
Xiangmin Cui 5%+ holder (13G) 3,065,702 7.40% 2026-09-30
Jiangwen Majeti
Director · +145,030 options
Insider 50,914 0.12% 2024-12-31
Min Qiu
Chief Executive Officer · +100,000 options
Insider 2,498 0.01% 2026-07-01
Yingjuan June Lu
Chief Scientific Officer · +36,821 options
Insider 100 0.00% 2024-12-31

Share count 41,409,059 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BYSI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BYSI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.